Dongfang Wealth Securities released a research report on April 18 stating that it gave Rongtai Health (603579.SH) an increase in its holdings. The main reasons for the rating include: 1) the company's release of the 2023 annual report and the performance forecast for the first quarter of 2024; 2) weak global consumer demand and pressure on the revenue side; 3) supply chain optimization, product restructuring, and profitability improvement; 4) increase in dividend rates to give back to shareholders. (Mainichi Keizai Shimbun)
东方财富证券4月18日发布研报称，给予荣泰健康（603579.SH）增持评级。评级理由主要包括：1）公司发布2023年年报及2024年一季度业绩预告；2）全球消费需求疲软，营收端承压；3）供应链优化、产品结构调整，盈利能力提升；4）分红率提升，回馈股东。（每日经济新闻）
Dongfang Wealth Securities released a research report on April 18 stating that it gave Rongtai Health (603579.SH) an increase in its holdings. The main reasons for the rating include: 1) the company's release of the 2023 annual report and the performance
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.